X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs STERLING BIOTECH - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD STERLING BIOTECH ORCHID PHARMA LTD/
STERLING BIOTECH
 
P/E (TTM) x -0.5 -1.6 - View Chart
P/BV x 0.4 0.1 585.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   STERLING BIOTECH
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
STERLING BIOTECH
Dec-13
ORCHID PHARMA LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs19411 1,847.6%   
Low Rs353 1,029.4%   
Sales per share (Unadj.) Rs276.526.8 1,031.3%  
Earnings per share (Unadj.) Rs-79.2-15.0 529.6%  
Cash flow per share (Unadj.) Rs-43.5-5.5 795.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.954.9 98.3%  
Shares outstanding (eoy) m70.45267.87 26.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.3 159.7%   
Avg P/E ratio x-1.4-0.5 311.1%  
P/CF ratio (eoy) x-2.6-1.3 207.1%  
Price / Book Value ratio x2.10.1 1,676.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,862 433.3%   
No. of employees `0002.81.4 206.8%   
Total wages/salary Rs m2,527547 462.1%   
Avg. sales/employee Rs Th6,956.15,303.3 131.2%   
Avg. wages/employee Rs Th902.5403.8 223.5%   
Avg. net profit/employee Rs Th-1,993.0-2,959.0 67.4%   
INCOME DATA
Net Sales Rs m19,4777,181 271.2%  
Other income Rs m40743 955.9%   
Total revenues Rs m19,8847,223 275.3%   
Gross profit Rs m1,103947 116.4%  
Depreciation Rs m2,5192,543 99.1%   
Interest Rs m5,2274,377 119.4%   
Profit before tax Rs m-6,236-5,931 105.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125-1,924 6.5%   
Profit after tax Rs m-5,580-4,007 139.3%  
Gross profit margin %5.713.2 42.9%  
Effective tax rate %2.032.4 6.2%   
Net profit margin %-28.7-55.8 51.3%  
BALANCE SHEET DATA
Current assets Rs m11,01414,335 76.8%   
Current liabilities Rs m32,06049,809 64.4%   
Net working cap to sales %-108.1-494.0 21.9%  
Current ratio x0.30.3 119.4%  
Inventory Days Days95403 23.5%  
Debtors Days Days34171 19.7%  
Net fixed assets Rs m29,44055,432 53.1%   
Share capital Rs m705268 263.0%   
"Free" reserves Rs m2,04313,935 14.7%   
Net worth Rs m3,80014,701 25.8%   
Long term debt Rs m9,0189,478 95.1%   
Total assets Rs m46,51073,988 62.9%  
Interest coverage x-0.2-0.4 54.4%   
Debt to equity ratio x2.40.6 368.1%  
Sales to assets ratio x0.40.1 431.5%   
Return on assets %-0.80.5 -151.7%  
Return on equity %-146.9-27.3 538.9%  
Return on capital %-3.7-6.4 58.1%  
Exports to sales %37.925.9 146.2%   
Imports to sales %22.60.2 13,314.9%   
Exports (fob) Rs m7,3781,860 396.7%   
Imports (cif) Rs m4,40612 36,115.6%   
Fx inflow Rs m7,5131,860 404.0%   
Fx outflow Rs m5,64925 22,695.1%   
Net fx Rs m1,8651,835 101.6%   
CASH FLOW
From Operations Rs m1,6821,719 97.8%  
From Investments Rs m-9,860-3,148 313.2%  
From Financial Activity Rs m6,6441,426 465.9%  
Net Cashflow Rs m-1,535-3 45,147.1%  

Share Holding

Indian Promoters % 32.3 33.9 95.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.0 -  
FIIs % 3.3 9.9 33.3%  
ADR/GDR % 4.6 16.9 27.2%  
Free float % 55.3 39.3 140.7%  
Shareholders   84,811 21,482 394.8%  
Pledged promoter(s) holding % 54.9 55.9 98.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 23, 2018 03:35 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS